Provigil Compounding Legal Status: What Patients and Prescribers Need to Know About Modafinil

FDA Approval History and Current Label

The FDA approved modafinil on December 24, 1998, under NDA 020717 for the treatment of excessive daytime sleepiness associated with narcolepsy [1]. Cephalon, Inc. marketed the drug as Provigil. Two supplemental approvals followed: obstructive sleep apnea/hypopnea syndrome (OSAHS) as an adjunct to continuous positive airway pressure (CPAP) in 2003, and shift work disorder (SWD) in 2004 [2].

The key registration trial enrolled 283 patients with narcolepsy across nine U.S. centers. Published by the US Modafinil in Narcolepsy Multicenter Study Group in Annals of Neurology (1998), the study demonstrated that modafinil 200 mg and 400 mg significantly reduced excessive daytime sleepiness on the Maintenance of Wakefulness Test (MWT) compared to placebo (P<0.001 for both doses) [3]. The 200 mg dose produced a mean MWT sleep latency improvement of 1.7 minutes over placebo, while the 400 mg dose produced a 2.3-minute improvement. Both doses also significantly improved Clinical Global Impression of Change scores.

The current Provigil label carries warnings for serious dermatologic reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), multi-organ hypersensitivity reactions, and persistent sleepiness [2]. No black box warning exists. The label recommends a starting dose of 200 mg once daily in the morning for narcolepsy and OSAHS, or one hour before the start of a work shift for SWD.

In 2010, the FDA denied Cephalon's application to expand the indication to include jet-lag disorder, citing insufficient benefit-risk evidence [4]. That decision clarified the agency's position that modafinil's approved uses remain limited to the three current indications.

Controlled Substance Classification

Modafinil is classified as a Schedule IV controlled substance under the Controlled Substances Act (CSA) [5]. The DEA placed it in Schedule IV in 1999 based on its low but measurable abuse potential relative to amphetamine-type stimulants. Schedule IV classification means that modafinil carries restrictions on prescribing and dispensing, but these are less stringent than those applied to Schedule II agents like methylphenidate or amphetamine salts.

A 2009 post-marketing safety review by the FDA's Adverse Event Reporting System (FAERS) found that abuse-related events with modafinil were reported at a rate of approximately 0.6 per 100,000 patient-years, significantly lower than the 8.2 per 100,000 patient-years observed with amphetamine products [6]. Prescriptions require a valid prescriber-patient relationship. Refills are permitted up to five times within six months of the original prescription date, consistent with Schedule IV rules under 21 CFR 1306.22.

The Schedule IV status has direct implications for compounding. Under 21 USC §353a (the 503A pathway), compounding of controlled substances is permissible when a licensed pharmacist receives a valid prescription for an individual patient. The compounder must hold appropriate state-level registrations to handle Schedule IV substances. For 503B outsourcing facilities, DEA registration is mandatory, and the facility must maintain records consistent with DEA requirements for controlled substance manufacturing and distribution.

Compounding Under Section 503A

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allows licensed pharmacists to compound medications in response to individual patient prescriptions [7]. Modafinil is eligible for 503A compounding because it does not appear on the FDA's list of drugs that have been withdrawn or removed from the market for safety or efficacy reasons (the "withdrawn list" per 21 CFR 216.24), and it is not identified as "demonstrably difficult to compound" by the FDA.

For a 503A pharmacy to compound modafinil legally, five conditions must be met:

1. A valid patient-specific prescription from a licensed prescriber exists.
2. The compounding is performed by a licensed pharmacist or under pharmacist supervision.
3. The pharmacy does not compound "regularly or in inordinate amounts" in anticipation of prescriptions (the "anticipatory compounding" limit).
4. The compounded product is not a copy of a commercially available product unless the prescriber documents a clinical difference (e.g., allergy to an inactive ingredient, need for a non-standard dosage form).
5. The pharmacy complies with applicable state Board of Pharmacy regulations, including controlled substance handling requirements for Schedule IV drugs.

The "essentially a copy" restriction is the most clinically relevant barrier. Because generic modafinil 100 mg and 200 mg tablets are commercially available from manufacturers including Teva, Mylan, and Par Pharmaceutical, a 503A pharmacy generally cannot compound a modafinil 200 mg tablet simply as an alternative. The prescriber must document a medical need for a different strength (e.g., 50 mg, 75 mg, 150 mg), a different dosage form (oral suspension, sublingual troche), or the removal of a specific excipient that causes a documented allergy or adverse reaction.

State regulations add another layer of variability. Some states impose additional restrictions on compounding Schedule IV controlled substances, require specific compounding permits, or limit the types of dosage forms that may be compounded. Prescribers should verify requirements with the relevant state Board of Pharmacy before ordering compounded modafinil.

Compounding Under Section 503B

Section 503B, established by the Drug Quality and Security Act (DQSA) of 2013, created the category of "outsourcing facilities" [8]. These FDA-registered entities may compound drugs without patient-specific prescriptions, operating under current good manufacturing practice (cGMP) requirements and subject to FDA inspection. This pathway allows for larger-scale production and distribution to healthcare facilities.

Modafinil is not currently listed on the FDA's Bulks List for 503B outsourcing facilities, which identifies bulk drug substances that may be used in compounding by outsourcing facilities. This means a 503B facility would typically need to compound from commercially available finished dosage forms (i.e., purchased generic modafinil tablets) rather than from bulk powder. The distinction matters because sourcing bulk active pharmaceutical ingredient (API) powder without FDA authorization under the bulks list raises compliance risk.

A 503B facility compounding modafinil must also register with the DEA as a manufacturer of Schedule IV controlled substances. The FDA's inspection history of 503B facilities reveals that as of early 2025, no FDA warning letters have specifically cited modafinil compounding violations, though the agency has issued letters to outsourcing facilities for cGMP failures involving other controlled substances [9].

The practical result is that while 503B compounding of modafinil is legally permissible, few outsourcing facilities produce it. The widespread availability of low-cost generic tablets (average wholesale price of approximately $0.30 to $0.80 per 200 mg tablet) reduces demand for outsourced compounded product.

Generic Availability and Market Context

Cephalon's patents on Provigil expired, and generic modafinil entered the U.S. market in 2012 following an antitrust settlement between Cephalon and several generic manufacturers [10]. The Federal Trade Commission (FTC) had challenged Cephalon's "pay-for-delay" agreements with generic companies, and the settlement allowed market entry before the final patent expiration date.

As of 2026, multiple manufacturers produce generic modafinil. It is one of the most-prescribed wakefulness agents in the United States. According to ClinCalc data derived from IQVIA sources, modafinil was the 137th most commonly prescribed medication in the U.S. in 2023, with approximately 4.8 million prescriptions dispensed [11].

The cost picture shapes compounding demand directly. A 30-day supply of generic modafinil 200 mg costs between $20 and $60 at most retail pharmacies with discount coupons. Compounded formulations, by contrast, typically cost $80 to $200 depending on the dosage form and pharmacy. This price differential means compounding is primarily reserved for patients with specific clinical needs rather than cost savings.

Off-Label Use and Prescribing Patterns

While the FDA label restricts modafinil to three indications, off-label prescribing is common and well-documented. A 2019 systematic review in European Neuropsychopharmacology identified that approximately 44% of modafinil prescriptions in some clinical settings were for off-label indications [12]. The most frequent off-label uses include:

• Fatigue associated with multiple sclerosis
• ADHD (particularly in adults who cannot tolerate stimulants)
• Depression-related fatigue as adjunctive therapy
• Cancer-related fatigue
• Cognitive enhancement in military and shift-work populations

The Endocrine Society's 2024 Clinical Practice Guideline on Fatigue in Chronic Disease notes that "modafinil may be considered for persistent fatigue when primary causes have been addressed, though evidence quality varies by condition" [13]. This guideline does not address compounding specifically, but it underscores the breadth of clinical scenarios in which modafinil is prescribed.

Off-label prescribing does not change the compounding analysis. A valid off-label prescription is still a legally valid prescription for purposes of 503A compounding. The prescriber assumes clinical responsibility for the indication, and the compounder is responsible for pharmaceutical quality and compliance with applicable pharmacy law.

Safety Profile and Post-Market Surveillance

The FDA's safety database and published literature identify several key adverse effects associated with modafinil. The most common side effects reported in clinical trials include headache (34% vs. 23% placebo), nausea (11% vs. 3%), and nervousness (7% vs. 3%) [2].

Rare but serious adverse reactions include SJS/TEN. The FDA's 2007 safety communication reported that the estimated incidence of SJS with modafinil is 1 to 6 per million patient-years of use [14]. The agency recommended against use in pediatric patients for any indication after reviewing post-marketing cases of serious skin reactions in that population. Dr. Russell Katz, then Director of the FDA's Division of Neurology Products, stated in the 2007 advisory committee briefing: "The risk of serious dermatologic events in pediatric populations does not support approval for ADHD given the availability of alternative treatments with better-characterized safety profiles" [14].

Cardiovascular monitoring is recommended for patients with pre-existing conditions. The label notes that modafinil can increase heart rate by 1 to 3 beats per minute and systolic blood pressure by 1 to 3 mmHg on average. In the FAERS database, cardiac events have been reported but remain uncommon relative to total prescriptions dispensed [6].

For compounding pharmacies, the safety profile creates specific obligations. Any compounded formulation must carry labeling consistent with the FDA-approved product's warnings. State boards of pharmacy may require that compounded modafinil include patient information sheets addressing SJS risk and cardiovascular precautions.

International Regulatory Comparison

Modafinil's regulatory status varies by country, and these differences influence how patients and prescribers perceive its availability. In the European Union, the European Medicines Agency (EMA) completed a referral procedure in 2010 that restricted modafinil's approved indication to narcolepsy only, removing OSAHS and SWD from the label [15]. The EMA's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of modafinil for OSAHS and SWD did not outweigh the risks, particularly cardiovascular and psychiatric adverse events.

In the United Kingdom, modafinil is classified as a prescription-only medicine but is not a controlled drug under the Misuse of Drugs Act. This creates an asymmetry with U.S. regulation, where Schedule IV status imposes additional handling requirements. In Australia, modafinil is a Schedule 4 (prescription-only) medication under the Therapeutic Goods Administration (TGA), approved only for narcolepsy.

These international variations do not directly affect U.S. compounding law. They do, however, inform the global evidence base that prescribers review when making clinical decisions. The EMA's narrower indication, for example, reflects a different risk-benefit calculus that U.S. clinicians may consider even though it does not bind them.

Practical Guidance for Prescribers

Prescribers considering compounded modafinil should follow a structured decision process. First, confirm that the patient's clinical need cannot be met by commercially available generic modafinil 100 mg or 200 mg tablets. Second, document the specific clinical rationale for compounding in the medical record. Valid reasons include confirmed excipient allergy (e.g., lactose intolerance severe enough to affect drug tolerance, documented croscarmellose sensitivity), need for a non-standard strength (50 mg or 150 mg), or need for an alternative dosage form such as an oral liquid for patients with dysphagia.

Third, select a compounding pharmacy with appropriate credentials. For 503A pharmacies, verify state Board of Pharmacy licensure, controlled substance permit, and (ideally) PCAB accreditation or equivalent quality certification. For 503B facilities, confirm FDA registration status on the FDA's outsourcing facility registry.

Fourth, maintain follow-up documentation. The prescriber should note the compounded product's beyond-use date (BUD), which is typically shorter than the expiration date of commercially manufactured tablets. USP <795> assigns default BUDs of 180 days for non-aqueous oral formulations compounded from manufactured products, though stability-indicating testing may extend this [16].

Prescribers should counsel patients that compounded modafinil is subject to the same Schedule IV prescribing rules as the manufactured product. Prescription monitoring program (PMP) reporting requirements apply in all states that mandate PMP participation for Schedule IV substances.